Mineralocorticoid Antagonism and Diabetic Kidney Disease - PubMed (original) (raw)
Review
Mineralocorticoid Antagonism and Diabetic Kidney Disease
Yuliya Lytvyn et al. Curr Diab Rep. 2019.
Abstract
Purpose of review: Type 2 diabetes (T2D) is associated with an increased risk of diabetic kidney disease (DKD), cardiovascular disease, and heart failure, in part through activation of the renin-angiotensin-aldosterone system (RAAS). Although recent cardiovascular outcome trials have identified newer therapeutic agents such as sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1)-receptor agonists that reduce the risk of these complications, patients still exhibit residual cardiorenal morbidity and mortality. Accordingly, the identification of pharmacological agents that attenuate micro- and macrovascular complications related to T2D is a major priority. Our aim was to review evidence for the role of novel mineralocorticoid receptor antagonists (MRAs) that are being developed as adjunctive therapies to reduce the risk of DKD and cardiovascular disease in the setting of T2D.
Recent findings: Dual RAAS blockade with angiotensin-converting enzyme (ACE) inhibitor plus angiotensin receptor blockade (ARB) or ARB plus renin inhibition increases serious adverse events such as acute kidney injury and stroke. Due to the potential for these serious side effects, more recent interest has focused on newer, more selective non-steroidal MRAs such as finerenone as cardiorenal protective therapies. Finerenone reduces albuminuria in the setting of DKD in patients with T2D and has a lower risk of hyperkalemia compared to currently available MRAs. Novel MRAs such as finerenone have the potential to reduce the risk of DKD progression in patients with T2D. The impact of finerenone on hard, long-term cardiorenal endpoints is being examined in the FIGARO and FIDELIO trials in patients with DKD.
Keywords: Diabetes; Diabetic kidney disease; Mineralocorticoid receptor antagonist.
Similar articles
- Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease.
Lerma E, White WB, Bakris G. Lerma E, et al. Postgrad Med. 2023 Apr;135(3):224-233. doi: 10.1080/00325481.2022.2060598. Epub 2022 Apr 20. Postgrad Med. 2023. PMID: 35392754 Review. - The association between dual RAAS inhibition and risk of acute kidney injury and hyperkalemia in patients with diabetic kidney disease: a systematic review and meta-analysis.
Whitlock R, Leon SJ, Manacsa H, Askin N, Rigatto C, Fatoba ST, Farag YMK, Tangri N. Whitlock R, et al. Nephrol Dial Transplant. 2023 Oct 31;38(11):2503-2516. doi: 10.1093/ndt/gfad101. Nephrol Dial Transplant. 2023. PMID: 37309038 Free PMC article. - Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Nowack C, Kolkhof P, Ferreira AC, Schloemer P, Filippatos G; on behalf of the FIDELIO-DKD study investigators; FIDELIO-DKD study investigators. Bakris GL, et al. Am J Nephrol. 2019;50(5):333-344. doi: 10.1159/000503713. Epub 2019 Oct 25. Am J Nephrol. 2019. PMID: 31655812 Free PMC article. Clinical Trial. - Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.
Ruilope LM, Agarwal R, Anker SD, Bakris GL, Filippatos G, Nowack C, Kolkhof P, Joseph A, Mentenich N, Pitt B; FIGARO-DKD study investigators. Ruilope LM, et al. Am J Nephrol. 2019;50(5):345-356. doi: 10.1159/000503712. Epub 2019 Oct 30. Am J Nephrol. 2019. PMID: 31665733 Free PMC article. Clinical Trial. - Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus.
Wish JB, Pergola P. Wish JB, et al. Mayo Clin Proc Innov Qual Outcomes. 2022 Oct 15;6(6):536-551. doi: 10.1016/j.mayocpiqo.2022.09.002. eCollection 2022 Dec. Mayo Clin Proc Innov Qual Outcomes. 2022. PMID: 36277502 Free PMC article. Review.
Cited by
- SKP alleviates the ferroptosis in diabetic kidney disease through suppression of HIF-1α/HO-1 pathway based on network pharmacology analysis and experimental validation.
Yan Y, Yuan N, Chen Y, Ma Y, Chen A, Wang F, Yan S, He Z, He J, Zhang C, Wang H, Wang M, Diao J, Xiao W. Yan Y, et al. Chin Med. 2024 Feb 25;19(1):31. doi: 10.1186/s13020-024-00901-5. Chin Med. 2024. PMID: 38403669 Free PMC article. - Mineralocorticoid receptor antagonists for chronic heart failure: a meta-analysis focusing on the number needed to treat.
Geng C, Mao YC, Qi SF, Song K, Wang HF, Zhang ZY, Tian QB. Geng C, et al. Front Cardiovasc Med. 2023 Nov 6;10:1236008. doi: 10.3389/fcvm.2023.1236008. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 38028498 Free PMC article. Review. - Chronic kidney disease in type 1 diabetes: translation of novel type 2 diabetes therapeutics to individuals with type 1 diabetes.
Sridhar VS, Limonte CP, Groop PH, Heerspink HJL, Pratley RE, Rossing P, Skyler JS, Cherney DZI. Sridhar VS, et al. Diabetologia. 2024 Jan;67(1):3-18. doi: 10.1007/s00125-023-06015-1. Epub 2023 Oct 6. Diabetologia. 2024. PMID: 37801140 Review. - Identification of endoplasmic reticulum stress-related biomarkers of diabetes nephropathy based on bioinformatics and machine learning.
Su J, Peng J, Wang L, Xie H, Zhou Y, Chen H, Shi Y, Guo Y, Zheng Y, Guo Y, Dong Z, Zhang X, Liu H. Su J, et al. Front Endocrinol (Lausanne). 2023 Sep 1;14:1206154. doi: 10.3389/fendo.2023.1206154. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37745718 Free PMC article. - Mineralocorticoid receptor antagonists in cardiovascular translational biology.
Chilton RJ, Silva-Cardoso J. Chilton RJ, et al. Cardiovasc Endocrinol Metab. 2023 Aug 21;12(3):e0289. doi: 10.1097/XCE.0000000000000289. eCollection 2023 Sep. Cardiovasc Endocrinol Metab. 2023. PMID: 37614245 Free PMC article. Review.
References
- Diabetes Care. 2005 Sep;28(9):2106-12 - PubMed
- J Int Med Res. 2001 Jan-Feb;29(1):13-21 - PubMed
- Am J Nephrol. 2017;46(3):213-221 - PubMed
- J Cardiovasc Pharmacol. 2014 Jul;64(1):69-78 - PubMed
- Atherosclerosis. 2003 Feb;166(2):345-9 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous